ALDX Archives - BioTuesdays

Markets

SVB Leerink starts Aldeyra Therapeutics at OP; PT $22

SVB Leerink launched coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with an “outperform” rating and $22 price target. The stock closed at $12.07 on March 11. Two of the company’s lead investigational compounds...

March 12, 2021

Developments

Aldeyra initiates 3 Phase 2 trials of ADX-629

Aldeyra Therapeutics (NASDAQ:ALDX) launched three Phase 2 trials evaluating ADX-629 for the treatment of COVID-19, atopic asthma, and psoriasis. ADX-629 is an orally administered RASP inhibitor designed to modulate the...

December 17, 2020

Markets

BTIG starts Aldeyra Therapeutics at buy; PT $29

BTIG initiated coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and $29 price target. The stock closed at $6.86 on Oct. 15. Aldeyra is targeting reactive aldehyde species (RASP) for a range of...

October 16, 2020

Developments

Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial

Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 INVIGORATE trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. The trial will enroll some 120 patients to assess...

January 21, 2020

Developments

Aldeyra enrolls first patient in Phase 3 vitreoretinopathy trial

Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 GUARD trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads...

December 19, 2019

Developments

Aldeyra reports positive topline results from Phase 3 dry eye disease trial

Aldeyra Therapeutics (NASDAQ:ALDX) reported positive topline results from the first part of its adaptive Phase 3 trial of topical ocular reproxalap for the treatment of dry eye disease. Part 1 of the study assessed...

December 3, 2019

Developments

Aldeyra gets FDA fast track designation for vitreoretinopathy drug candidate

Aldeyra Therapeutics’ (NASDAQ:ALDX) ADX-2191 received FDA fast track designation for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads to severe retinal...

September 24, 2019

Tag - ALDX

SVB Leerink starts Aldeyra Therapeutics at OP; PT $22

Aldeyra initiates 3 Phase 2 trials of ADX-629

BTIG starts Aldeyra Therapeutics at buy; PT $29

Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial

Aldeyra enrolls first patient in Phase 3 vitreoretinopathy trial

Aldeyra reports positive topline results from Phase 3 dry eye disease trial

Aldeyra gets FDA fast track designation for vitreoretinopathy drug candidate

General

More